Drug Profile
HT 2157
Alternative Names: HT-2157Latest Information Update: 16 Feb 2016
Price :
$50
*
At a glance
- Originator Lundbeck A/S
- Developer Dart NeuroScience
- Class Nootropics
- Mechanism of Action Galanin type 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Major depressive disorder; Memory disorders
Most Recent Events
- 16 Feb 2016 Discontinued - Phase-II for Major depressive disorder in USA (PO) (NeuroScience pipeline, August 2015)
- 16 Feb 2016 Discontinued - Preclinical for Memory disorders in USA (PO)
- 12 Apr 2013 HT 2157 is still in Preclinical trials for Memory disorders in USA